Modulation of Immuno-biome during radio-sensitization of tumors by glycolytic inhibitors.
The tumor microenvironment (TME) comprising of stroma and various components of the immune system forms a pro-tumorigenic cocoon around the tumor cells where reprogramming of the metabolism manifesting in Warburg phenotype (enhanced aerobic glycolysis) occurs in tumor as well as non-tumor cells. This reprogramming plays a significant role in suppressing the immune attack on the tumor cells leading to cancer cell survival, proliferation and resistance to therapies. Therefore, there is a considerable interest in developing therapeutic strategies involving metabolic modifiers to improve the efficacy of therapy that restore immune competence, besides enhancing cytotoxicity of tumor cells by targeting metabolic reprogramming. Inhibitors of glycolysis like 2-deoxy-D-glucose (2-DG; a hexokinase inhibitor), dichloroacetate and small molecule inhibitors of lactate transport (MCT-1) are some of the metabolic modifiers investigated for their therapeutic as well as adjuvant potential. Among these, 2-DG has been widely investigated and established as an ideal adjuvant in the radio- and chemo- therapy of tumors. Selective modulation of the immuno-biome of the host-tumor interactions such as cytokine shifts, differential transcriptional regulation, abrogation of immunosuppressive network by 2-DG and reduction in the accumulation of tumor lactate by dichloroacetate are among the contributing factors for immune stimulation linked to the radiosensitization by glycolytic inhibitors.